Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cetuximab monotherapy or in combination with irinotecan for treatment of irinotecan-refractory metastatic colorectal cancer

Reporting in the latest issue of the New England Journal of Medicine, researchers have tested the efficacy of the monoclonal antibody cetuximab, either alone or in combination with a first line therapy, as a treatment in metastatic colorectal cancer.

News image

fiogf49gjkf04

Irinotecan is a first-line treatment for colorectal cancer that, along with other therapies, has helped increase the median survival among colorectal cancer patients from 12 months to about 18 to 21 months over the 10 years.

However, some patients do not respond to treatment with irinotecan and so other therapies are required for such patients.

A research team from hospitals across Europe has therefore investigated the use of cetuximab, a monoclonal antibody that binds with high specificity to the epidermal growth factor receptor (EGFR).

This receptor is of relevance in colorectal cancer because in up to 80% of patients with colorectal cancer, there is up-regulation and expression of the EGFR gene. Furthermore, expression of the gene has been shown to be associated with poor survival.

Through binding of its ligand (epidermal growth factor, or transforming growth factor-) EGFR is involved in signaling pathways that become deregulated in cancer cells, including cell differentiation, proliferation, migration, angiogenesis and apoptosis.

Cetuximab has clinically significant activity in patients with irinotecan-refractory colorectal cancer
New England Journal of Medicine

By binding to EGFR, cetuximab blocks activation of these signaling pathways, thus helping to control the cancerous activities of the cells on which EGFR is expressed. In addition, cetuximab has also been shown in experimental systems to enhance the effects of irinotecan and radiotherapy.

Led by Dr David Cunningham, from the Royal Marsden Hospital, in Surrey, England, the research team compared the efficacy of cetuximab alone with that of cetuximab in combination with irinotecan in patients with metastatic colorectal cancer that was refractory to treatment with irinotecan.

329 patients whose disease had progressed during or within 3 months after treatment with an irinotecan-based regimen were randomly assigned to receive either cetuximab and irinotecan (218 patients) or cetuximab monotherapy (111 patients).

Cetuximab was administered at an initial dose of 400 mg/m2, followed by weekly infusions of 250 mg/m2, while patients receiving the combination therapy received their irinotecan at the same dose and schedule as that given during their most recent prestudy therapy.

In cases of disease progression, the addition of irinotecan to cetuximab monotherapy was permitted.

Tumor response was evaluated every 6 weeks for the first 24 weeks and then at 3 month intervals, using either CT or MRI scans.

Each patient was evaluated radiologically for tumor response and was also evaluated for the time to tumor progression, survival and side-effects of treatment.

Patients receiving the combination therapy were found to respond at a significantly higher rate than those in the monotherapy cohort (22.9% compared to 10.8%).

The median time to progression was also significantly greater in the combination therapy group (4.1 compared to 1.5 months in the monotherapy group).

The median survival time was 8.6 months in the combination therapy group and 6.9 months in the monotherapy group.

However, toxic effects were more frequent in the combination-therapy group, but their severity and incidence were similar to those that would be expected with irinotecan alone.

Commenting on their findings, Dr Cunningham said that the observed tumor-response rate of 22.9% in the combination therapy group was clinically important, since after the standard drugs (including irinotecan) have failed, there are no accepted treatment options.

"Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer," he concluded.

N Engl J Med 2004; 351 (4): 337 - 345
23 July 2004

Go to top of page Email this page Email this page to a colleague

 23 November 2017 
Distance travelling for rectal cancer outcomes
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Pharmacological management of GERD
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us